__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Welcome to I.ON, the on-demand digital immunology programme designed to provide rheumatologists, dermatologists, immunologists and allergists treating PsO, chronic spontaneous urticaria, psoriatic arthritis and axial spondyloarthritis with first-class medical educational content.

What is PsO?

Psoriasis is a common, chronic, skin disease. There is no clear identifiable cause and no cure for the disease.1 It can occur at any age, but is most common in people aged 50–69 years.2

The reported prevalence of PsO is up to 12%, which means that at least 100 million individuals are affected worldwide.3,4

PsO greatly impacts people’s quality of life.1,2

Its symptoms are unpredictable and a number of external triggers are linked to their onset. PsO is associated with significant comorbidities, such as arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.1

PsO involves the skin and nails. Skin lesions are localised or generalised, and cause itching, stinging and pain.1

 

References

  1. World Health Organization. Global report on PSORIASIS. Available at: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_en... )(Accessed August 2021).
  2. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010: Results by Cause 1990–2010. Seattle: IHME; 2012.
  3. Gibbs S. Int J Dermatol 1996;35(9):633–639.
  4. Danielsen K, et al. Br J Dermatol 2013;168:1303–1310.
Rate this content: 
No votes yet
UK | October 2021 | 146359
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]